<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898779</url>
  </required_header>
  <id_info>
    <org_study_id>PQ Study 1</org_study_id>
    <nct_id>NCT02898779</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1</brief_title>
  <official_title>Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi, Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi, Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the comparative tolerability, metabolism and pharmacokinetics of individual
      enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation
      of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and
      SPQ and the racemic mixture RSPQ) in normal healthy human volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this project is to investigate the comparative tolerability,
      metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers.

      The overall approach is as follows: in 36 healthy volunteers with documented normal G6PD
      activity, we will administer a single oral dose of RPQ, SPQ, or RSPQ. At various times after
      dosing, we will draw blood samples, in which we will record the plasma levels of the parent
      drugs, along with plasma and urinary metabolites. The comparative pharmacokinetics,
      tolerability and hematological effects of these two enantiomers and the racemate will be
      assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Actual">March 1, 2018</completion_date>
  <primary_completion_date type="Actual">March 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: Plasma concentration of parent primaquine and carboyprimaquine following a single dose treatment with primaquine (racemate or enantiomers) not to exceed 45 mg</measure>
    <time_frame>between 0-24 Hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for primaquine up to 24 hours after the primaquine administration</measure>
    <time_frame>between 0-24 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) for primaquine up to 24 hours after the primaquine administration</measure>
    <time_frame>between 0-24 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration</measure>
    <time_frame>between 0-24 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of carboxyprimaquine, the major plasma metabolite of primaquine, up to 24 hours after primaquine administration</measure>
    <time_frame>between 0-24 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of selected metabolites primaquine (other than carboxyprimaquine) up to 24 hours after primaquine administration</measure>
    <time_frame>between 0-24 hours</time_frame>
    <description>This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers. The exact nature of these metabolites will be determined from previous animal and human studies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin and methemoglobin levels in the blood after administration of primaquine</measure>
    <time_frame>0-72 hours</time_frame>
    <description>To monitor hemoglobin and methemoglobin levels in normal human volunteers treated with single dose of primaquine not to exceed 45 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of Cytochrome P-450 (CYP)</measure>
    <time_frame>day 0</time_frame>
    <description>To determine correlation between metabolism of primaquine and CYP 2D6 genotype</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Cohort 1 ( Primaquine Low Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
Cohort 1 (Low Dose Level)- single dose of 15 mg of S-Primaquine and 15 mg of R-Primaquine compared to 30 mg RS-Primaquine over 24 hours. Participants will cross-over after a one week wash-out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (Primaquine High Dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions: Primaquine, R-Primaquine, S-Primaquine, SR Primaquine A single center, prospective, cross-over, randomized phase 1 trial. Thirty-six participants, enrolled into a two cohort pharmacokinetic study evaluating two dose levels of primaquine isomers.
Cohort 2 (High Dose Level)-single dose of 22.5 mg of S-Primaquine and 22.5 mg of R-Primaquine compared to 45 mg RS-Primaquine over 24 hours. Participants will cross-over among the treatment arms following a one week wash-out period between each.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine, R-Primaquine, S-Primaquine, SR Primaquine</intervention_name>
    <description>Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)
Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.
Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.
Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ.</description>
    <arm_group_label>Cohort 1 ( Primaquine Low Dose)</arm_group_label>
    <arm_group_label>Cohort 2 (Primaquine High Dose)</arm_group_label>
    <other_name>Primaquine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (18-60 years of age)

          -  Informed consent

          -  Healthy

        Exclusion Criteria:

          -  Known history of liver, kidney or hematological disease;

          -  known history of cardiac disease, arrhythmia, QT prolongation;

          -  Autoimmune disorder;

          -  Report of an active infection;

          -  Evidence of G6PD deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babu L Tekwani, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Mississippi Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Mississippi</name>
      <address>
        <city>Oxford</city>
        <state>Mississippi</state>
        <zip>38677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Avula B, Tekwani BL, Chaurasiya ND, Nanayakkara NP, Wang YH, Khan SI, Adelli VR, Sahu R, Elsohly MA, McChesney JD, Khan IA, Walker LA. Profiling primaquine metabolites in primary human hepatocytes using UHPLC-QTOF-MS with 13C stable isotope labeling. J Mass Spectrom. 2013 Feb;48(2):276-85. doi: 10.1002/jms.3122.</citation>
    <PMID>23378100</PMID>
  </results_reference>
  <results_reference>
    <citation>Avula B, Khan SI, Tekwani BL, Nanayakkara NP, McChesney JD, Walker LA, Khan IA. Analysis of primaquine and its metabolite carboxyprimaquine in biological samples: enantiomeric separation, method validation and quantification. Biomed Chromatogr. 2011 Sep;25(9):1010-7. doi: 10.1002/bmc.1557. Epub 2010 Nov 5.</citation>
    <PMID>21058417</PMID>
  </results_reference>
  <results_reference>
    <citation>Baker JK, McChesney JD. Differential metabolism of the enantiomers of primaquine. J Pharm Sci. 1988 May;77(5):380-2.</citation>
    <PMID>3411455</PMID>
  </results_reference>
  <results_reference>
    <citation>Lu H. Stereoselectivity in drug metabolism. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):149-58. Review.</citation>
    <PMID>17428147</PMID>
  </results_reference>
  <results_reference>
    <citation>Fasinu PS, Tekwani BL, Nanayakkara NP, Avula B, Herath HM, Wang YH, Adelli VR, Elsohly MA, Khan SI, Khan IA, Pybus BS, Marcsisin SR, Reichard GA, McChesney JD, Walker LA. Enantioselective metabolism of primaquine by human CYP2D6. Malar J. 2014 Dec 17;13:507. doi: 10.1186/1475-2875-13-507.</citation>
    <PMID>25518709</PMID>
  </results_reference>
  <results_reference>
    <citation>Fasinu PS, Avula B, Tekwani BL, Nanayakkara NP, Wang YH, Bandara Herath HM, McChesney JD, Reichard GA, Marcsisin SR, Elsohly MA, Khan SI, Khan IA, Walker LA. Differential kinetic profiles and metabolism of primaquine enantiomers by human hepatocytes. Malar J. 2016 Apr 19;15:224. doi: 10.1186/s12936-016-1270-1.</citation>
    <PMID>27093859</PMID>
  </results_reference>
  <results_reference>
    <citation>Graves PM, Gelband H, Garner P. Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission. Cochrane Database Syst Rev. 2015 Feb 19;(2):CD008152. doi: 10.1002/14651858.CD008152.pub4. Review. Update in: Cochrane Database Syst Rev. 2018 Feb 02;2:CD008152.</citation>
    <PMID>25693791</PMID>
  </results_reference>
  <results_reference>
    <citation>Jin X, Pybus BS, Marcsisin R, Logan T, Luong TL, Sousa J, Matlock N, Collazo V, Asher C, Carroll D, Olmeda R, Walker LA, Kozar MP, Melendez V. An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur J Drug Metab Pharmacokinet. 2014 Jun;39(2):139-46.</citation>
    <PMID>23797843</PMID>
  </results_reference>
  <results_reference>
    <citation>Mihaly GW, Ward SA, Edwards G, Orme ML, Breckenridge AM. Pharmacokinetics of primaquine in man: identification of the carboxylic acid derivative as a major plasma metabolite. Br J Clin Pharmacol. 1984 Apr;17(4):441-6.</citation>
    <PMID>6721990</PMID>
  </results_reference>
  <results_reference>
    <citation>Nanayakkara NP, Ager AL Jr, Bartlett MS, Yardley V, Croft SL, Khan IA, McChesney JD, Walker LA. Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinol ine succinate. Antimicrob Agents Chemother. 2008 Jun;52(6):2130-7. doi: 10.1128/AAC.00645-07. Epub 2008 Mar 31.</citation>
    <PMID>18378716</PMID>
  </results_reference>
  <results_reference>
    <citation>Nanayakkara NP, Tekwani BL, Herath HM, Sahu R, Gettayacamin M, Tungtaeng A, van Gessel Y, Baresel P, Wickham KS, Bartlett MS, Fronczek FR, Melendez V, Ohrt C, Reichard GA, McChesney JD, Rochford R, Walker LA. Scalable preparation and differential pharmacologic and toxicologic profiles of primaquine enantiomers. Antimicrob Agents Chemother. 2014 Aug;58(8):4737-44. doi: 10.1128/AAC.02674-13. Epub 2014 Jun 9.</citation>
    <PMID>24913163</PMID>
  </results_reference>
  <results_reference>
    <citation>Potter BM, Xie LH, Vuong C, Zhang J, Zhang P, Duan D, Luong TL, Bandara Herath HM, Dhammika Nanayakkara NP, Tekwani BL, Walker LA, Nolan CK, Sciotti RJ, Zottig VE, Smith PL, Paris RM, Read LT, Li Q, Pybus BS, Sousa JC, Reichard GA, Marcsisin SR. Differential CYP 2D6 metabolism alters primaquine pharmacokinetics. Antimicrob Agents Chemother. 2015 Apr;59(4):2380-7. doi: 10.1128/AAC.00015-15. Epub 2015 Feb 2.</citation>
    <PMID>25645856</PMID>
  </results_reference>
  <results_reference>
    <citation>Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013 Jun 20;12:212. doi: 10.1186/1475-2875-12-212.</citation>
    <PMID>23782898</PMID>
  </results_reference>
  <results_reference>
    <citation>Saunders D, Vanachayangkul P, Imerbsin R, Khemawoot P, Siripokasupkul R, Tekwani BL, Sampath A, Nanayakkara NP, Ohrt C, Lanteri C, Gettyacamin M, Teja-Isavadharm P, Walker L. Pharmacokinetics and pharmacodynamics of (+)-primaquine and (-)-primaquine enantiomers in rhesus macaques (Macaca mulatta). Antimicrob Agents Chemother. 2014 Dec;58(12):7283-91. doi: 10.1128/AAC.02576-13. Epub 2014 Sep 29.</citation>
    <PMID>25267666</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt LH, Alexander S, Allen L, Rasco J. Comparison of the curative antimalarial activities and toxicities of primaquine and its d and l isomers. Antimicrob Agents Chemother. 1977 Jul;12(1):51-60.</citation>
    <PMID>407841</PMID>
  </results_reference>
  <results_reference>
    <citation>Tekwani BL, Walker LA. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr Opin Infect Dis. 2006 Dec;19(6):623-31. Review.</citation>
    <PMID>17075340</PMID>
  </results_reference>
  <results_reference>
    <citation>Tekwani BL, Avula B, Sahu R, Chaurasiya ND, Khan SI, Jain S, Fasinu PS, Herath HM, Stanford D, Nanayakkara NP, McChesney JD, Yates TW, ElSohly MA, Khan IA, Walker LA. Enantioselective pharmacokinetics of primaquine in healthy human volunteers. Drug Metab Dispos. 2015 Apr;43(4):571-7. doi: 10.1124/dmd.114.061127. Epub 2015 Jan 30.</citation>
    <PMID>25637634</PMID>
  </results_reference>
  <results_reference>
    <citation>Vale N, Moreira R, Gomes P. Primaquine revisited six decades after its discovery. Eur J Med Chem. 2009 Mar;44(3):937-53. doi: 10.1016/j.ejmech.2008.08.011. Epub 2008 Sep 11. Review.</citation>
    <PMID>18930565</PMID>
  </results_reference>
  <results_reference>
    <citation>VÃ¡squez-Vivar J, Augusto O. Hydroxylated metabolites of the antimalarial drug primaquine. Oxidation and redox cycling. J Biol Chem. 1992 Apr 5;267(10):6848-54.</citation>
    <PMID>1313024</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

